Interleukin-6 ＂Trans-Signaling＂ and Ischemic Vascular Disease: The Important Role of Soluble gp130

Inflammation plays a major role in the onset of cardiovascular disease (CVD). Interleukine-6 (IL-6) is a multifunctional cytokine involved both in the beneficial acute inflammatory response and in the detrimental chronic low-grade systemic inflammation. Large genetic human studies, using Mendelian r...

Full description

Saved in:
Bibliographic Details
Published in:Mediators of Inflammation 2017-01, Vol.2017 (2017), p.1-6
Main Authors: Morieri, Mario Luca, Zuliani, Giovanni, Passaro, Angelina
Format: Article
Language:English
Subjects:
Animals
Atherosclerosis
Atherosclerosis - immunology
Atherosclerosis - metabolism
Binding sites
Blood circulation disorders
Cardiovascular disease
Cardiovascular Diseases - immunology
Cardiovascular Diseases - metabolism
Cytokine Receptor gp130 - metabolism
Cytokines
Glycoproteins
Health aspects
Humans
Hypotheses
Inflammation
Inflammation - immunology
Inflammation - metabolism
Insulin resistance
Interleukin-6
Interleukin-6 - metabolism
Metabolism
Models, Biological
Physiological aspects
Prevention
Proteins
Recruitment
Review
Risk Factors
Rodents
Signal transduction
Signal Transduction - physiology
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inflammation plays a major role in the onset of cardiovascular disease (CVD). Interleukine-6 (IL-6) is a multifunctional cytokine involved both in the beneficial acute inflammatory response and in the detrimental chronic low-grade systemic inflammation. Large genetic human studies, using Mendelian randomization approaches, have clearly showed that IL-6 pathway is causally involved in the onset of myocardial infarction. At the same time, IL-6 pathway is divided into two arms: classic signaling (effective in hepatocytes and leukocytes) and trans-signaling (with ubiquitous activity). Trans-signaling is known to be inhibited by the circulating soluble glycoprotein 130 (sgp130). In animal and in vitro models, trans-signaling inhibition with sgp130 antibody clearly shows a beneficial effect on inflammatory disease and atherosclerosis. Conversely, epidemiological data report inconsistent results between sgp130 levels and CV risk factors as well as CV outcome. We have reviewed the literature to understand the role of sgp130 and to find the evidence in favor of or against a possible clinical application of sgp130 treatment in the prevention of cardiovascular disease.
ISSN:0962-9351
1466-1861
DOI:10.1155/2017/1396398